ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 479,40
-0,68%
Dow Jones
39 118,86
-0,12%
DAX
18 235,45
0,17%
Brent Oil
84,85
0,00%
Bitcoin
60 860,30
-0,05%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Sensei Biotherapeutics Inc (SNSE)

  7. Sensei Biotherapeutics Inc (SNSE) Actualités

SNSE

Sensei Biotherapeutics (SNSE)

Sensei Biotherapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SNSE
DateHeureSourceTitreSymboleSociété
13/06/202423h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
13/06/202422h45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
09/05/202422h31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNSESensei Biotherapeutics Inc
07/11/202313h30GlobeNewswire Inc.Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:SNSESensei Biotherapeutics Inc
03/11/202321h05GlobeNewswire Inc.Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual MeetingNASDAQ:SNSESensei Biotherapeutics Inc
02/11/202321h50Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
01/11/202312h30GlobeNewswire Inc.Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business OfficerNASDAQ:SNSESensei Biotherapeutics Inc
25/10/202315h05GlobeNewswire Inc.Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual MeetingNASDAQ:SNSESensei Biotherapeutics Inc
23/10/202313h30GlobeNewswire Inc.Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023NASDAQ:SNSESensei Biotherapeutics Inc
27/09/202313h30GlobeNewswire Inc.Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron’s Libtayo®NASDAQ:SNSESensei Biotherapeutics Inc
21/09/202313h30GlobeNewswire Inc.Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy ConferenceNASDAQ:SNSESensei Biotherapeutics Inc
13/09/202313h30GlobeNewswire Inc.Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer ImmunotNASDAQ:SNSESensei Biotherapeutics Inc
30/08/202313h30GlobeNewswire Inc.Sensei Biotherapeutics to Participate in Upcoming Investor ConferencesNASDAQ:SNSESensei Biotherapeutics Inc
17/08/202323h15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SNSESensei Biotherapeutics Inc
03/08/202313h30GlobeNewswire Inc.Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:SNSESensei Biotherapeutics Inc
02/08/202313h30GlobeNewswire Inc.Sensei Biotherapeutics to Participate in Canaccord Genuity’s 43rd Annual Growth ConferenceNASDAQ:SNSESensei Biotherapeutics Inc
27/06/202315h01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SNSESensei Biotherapeutics Inc
15/06/202322h41Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:SNSESensei Biotherapeutics Inc
15/06/202322h32Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:SNSESensei Biotherapeutics Inc
02/06/202323h04Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SNSESensei Biotherapeutics Inc
01/06/202313h30GlobeNewswire Inc.Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid TumorsNASDAQ:SNSESensei Biotherapeutics Inc
23/05/202322h31Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:SNSESensei Biotherapeutics Inc
09/05/202322h34Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:SNSESensei Biotherapeutics Inc
09/05/202313h30GlobeNewswire Inc.Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:SNSESensei Biotherapeutics Inc
01/05/202322h19Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:SNSESensei Biotherapeutics Inc
20/04/202313h30GlobeNewswire Inc.Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking AntibodyNASDAQ:SNSESensei Biotherapeutics Inc
18/04/202322h05GlobeNewswire Inc.Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023NASDAQ:SNSESensei Biotherapeutics Inc
13/04/202313h30GlobeNewswire Inc.Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual ConferenceNASDAQ:SNSESensei Biotherapeutics Inc
30/03/202313h30GlobeNewswire Inc.Sensei Biotherapeutics to Participate in Cantor Fitzgerald’s Future of Oncology Virtual SymposiumNASDAQ:SNSESensei Biotherapeutics Inc
29/03/202323h18Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:SNSESensei Biotherapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SNSE

Dernières Valeurs Consultées

EU
PX1
CAC 40
EU
VIV
Vivendi
NASDAQ
AMZN
Amazon.com
EU
EN
Bouygues
EU
AI
Air Liquide
NYSE
DIS
Walt Disney
FTSE
UKX
FTSE 100
NYSE
NKE
Nike
NYSE
MRK
Merck
EU
ACA
Credit Agricole
NYSE
KO
Coca Cola
EU
CS
Axa
EU
RI
Pernod Ricard
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés